Fig 1.
MDV, Medical Data Vision; SCT, stem cell transplantation. Note: ICD10 codes I12.0, I13.1, N03.2 -N03.7, N05.2 -N05.7, N18.x, N19.x, N25.0, Z49.0-Z49.2, Z94.0, and Z99.2 were selected to identify renal impairment.
Table 1.
Baseline demographic and clinical characteristics.
Fig 2.
Regimen selection for induction therapy before SCT and post-SCT therapy in the SCT-conducted group.
(A) 2003 to 2015 induction therapy before SCT, (B) 2016 to 2020 induction therapy before SCT, (C) 2003 to 2015 post-SCT therapy, (D) 2016 to 2020 post-SCT therapy. DRd, daratumumab/lenalidomide/dexamethasone; IRd, ixazomib/lenalidomide/dexamethasone; IXA, ixazomib; KRd, carfilzomib/lenalidomide/dexamethasone; Rd, lenalidomide/dexamethasone; SCT, stem cell transplantation; VAD/VAd, vincristine/doxorubicin/dexamethasone; VCD/VCd, bortezomib/cyclophosphamide/dexamethasone; VD/Vd, bortezomib/dexamethasone; VRD/VRd, bortezomib/lenalidomide/dexamethasone. Note: Post-SCT therapy is the initiation date of the regimen between the date of SCT and post 4 months from SCT.
Fig 3.
First-line treatment duration by selected regimen in SCT not-conducted group (All population).
MP, melphalan/prednisolone; Rd, lenalidomide/dexamethasone; VCd, bortezomib/cyclophosphamide/dexamethasone; Vd, bortezomib/dexamethasone; VMP, bortezomib/melphalan/predonisolone; VRd, bortezomib/lenalidomide/dexamethasone. Note: Top 5 regimens in the proportion of use were selected.
Fig 4.
A: First-line treatment duration by selected regimen in SCT not-conducted group (aged >70 years). B: First-line treatment duration by selected regimen in SCT not-conducted group (aged ≤70 years). Cy+Dex, cyclophosphamide/dexamethasone; MP, melphalan/prednisolone; Rd, lenalidomide/dexamethasone; VCd, bortezomib/cyclophosphamide/dexamethasone; Vd, bortezomib/dexamethasone; VMP, bortezomib/melphalan/predonisolone; VRd, bortezomib/lenalidomide/dexamethasone. Note: Top 5 regimens in the proportion of use were selected.
Table 2.
Attrition rates by the line of therapy (2003–2015, and 2016–2020).
Fig 5.
A. Kaplan-Meier curve for time to inpatient death by the lines of treatment for SCT-conducted group in 2003–2015 and 2016–2020 cohorts. B. Kaplan-Meier curve for time to inpatient death by the lines of treatment for SCT not-conducted group in 2003–2015 and 2016–2020 cohorts. SCT, stem cell transplantation.